Ovid Therapeutics (OVID) executive compensation, 2026 proxy

Margaret Alexander, President and Chief Executive Officer and Former Chief Operating Officer, was paid $1M in 2025, down 38% from $1.7M the year before.

Filed
April 27, 2026
Annual meeting
June 10, 2026
Pay year
2025
Named executives
3
CEO total pay
$1M-38% vs prior year
CEO pay in equity
14%$143,272 in awards
CEO 2025 Salary
$515,000Margaret Alexander
Former CEO 2025 Salary
$644,054Jeremy M. Levin
CEO Target Bonus
45%Percentage of annual base salary
Performance Attainment
150%Achievement level for 2025

How Alexander was paid

$1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary50%Stock awards2%Option awards12%Non-equity incentive34%All other compensation1%

Named executive officers

ExecutiveTotal
Jeremy M. Levin, DPhil, MB BChirExecutive Chairman and Former Chief Executive Officer$1,934,699
Margaret AlexanderPresident and Chief Executive Officer and Former Chief Operating Officer$1,022,272
Jeffrey RonaChief Business & Financial Officer$969,164

What changed and why

  • Margaret Alexander succeeded Dr. Levin as Chief Executive Officer effective January 1, 2026.
  • $1MMargaret Alexander received a total compensation of $1,022,272 for fiscal 2025.
  • 150%Named executive officers achieved 150% of their performance objectives under the annual cash plan.
  • Dr. Levin was granted an option to purchase 1,650,000 shares of common stock in 2025.
  • $644KDr. Levin's base salary for 2025 was set at $644,054.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.